Fundraising Fox
Persevere Therapeutics
Chesterbrook, US · Founded 2025 · Delaware corporation
Find your way into Persevere Therapeutics
Sign up to see every warm intro you have to Persevere Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Persevere Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.
Founders & leadership
GB
Greg BoschFounder & CEOGreg Bosch is a life sciences executive who previously served as chairman and CEO of Panavance Therapeutics and CEO of Geistlich Pharma North America, where he led regenerative medicine efforts in the dental sector. He spent over two decades at Baxter International in roles including VP of Strategic Planning and General Manager of the BioSurgery Business, holds a B.A. in Public Policy from Duke University and an M.B.A. from DePaul University.
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2026
▶$1.6MraisedMar 2026 · 12 investors · OtherRule 506(b)
▶$1.6MraisedMar 2026 · 12 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Greg BoschExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.6M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Sapience TherapeuticsSapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
Jupiter BioventuresJupiter is a biotech company that discovers and develops new medicines across multiple therapeutic areas. The company is led by a team of experienced scientists and executives with a track record of creating approved drugs and founding successful biotech companies.
Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
C4 TherapeuticsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Companies working in the same space as Persevere Therapeutics.
In the news
Frequently asked questions
- What does Persevere Therapeutics do?
- Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.
- How much funding has Persevere Therapeutics raised?
- Persevere Therapeutics has disclosed $1.6M raised across 1 round.
- Where is Persevere Therapeutics headquartered?
- Persevere Therapeutics is headquartered in Chesterbrook, US.